NetworkNewsBreaks – Intellipharmaceutics International, Inc. (NASDAQ: IPCI) Receives ‘Hold’ Rating, Reduced PT at Aegis Capital

Aegis Capital has issued a ‘Hold’ rating and a lowered price target of $2 on shares of Intellipharmaceutics International (NASDAQ: IPCI). The news follows recent patent litigation from Purdue Pharma against Intellipharmaceutics regarding the New Drug Application (“NDA”) filing for its Rexista™ product candidate. The FDA is stayed for 30 months from granting final approval to the company’s Rexista™ as a result of these legal proceedings, unless a final declaration of the courts is entered that the patents are either invalid or are not infringed, or the matter is otherwise settled among the parties. The analyst noted the patent suit, as well as the extension of the FDA approval time it may cause, as the reason for downgrading the ‘Buy’ rating to ‘Hold’, as well as the lower price target.

For more information visit

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company’s patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (some of which have received FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Application (“ANDAs”) filed with the FDA (and one Abbreviated New Drug Submission filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s